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Abstract: Candida albicans forms extrem ely drug-resistant biofilms, w hich present a serious threat 
to public health globally. Biofilm-based infections are difficult to treat due to the lack of efficient 
antifungal therapeutics, resulting in an urgent demand for the developm ent of novel antibiofilm 
strategies. In this study, the antibiofilm activity of DiMIQ (5,11-dimethyl-5H-indolo[2,3-b]quinoline) 
was evaluated against C. albicans biofilms. DiMIQ is a synthetic derivative of indoquinoline alkaloid 
neocryptolepine isolated from a medicinal African plant, Cryptolepis sanguinolenta. Antifungal activity 
of DiMIQ was determined using the XTT assay, followed by cell wall and extracellular matrix profiling 
and cellular proteomes. Here, we demonstrated that DiMIQ inhibited C. albicans biofilm formation 
and altered fungal cell walls and the extracellular matrix. Cellular proteomics revealed inhibitory 
action against numerous translation-involved ribosomal proteins, enzymes involved in general 
energy producing processes and select amino acid metabolic pathways including alanine, aspartate, 
glutamate, valine, leucine and isoleucine. DiM IQ also stimulated pathways of cellular oxidation, 
metabolism of carbohydrates, amino acids (glycine, serine, threonine, arginine, phenylalanine, 
tyrosine, tryptophan) and nucleic acids (aminoacyl-tRNA biosynthesis, RNA transport, nucleotide 
metabolism). Our findings suggest that DiMIQ inhibits C. albicans biofilms by arresting translation 
and multidirectional pathway reshaping of cellular metabolism. Overall, this agent may provide a 
potent alternative to treating biofilm-associated Candida infections.
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1. Introduction
Candida spp. are opportunistic fungal pathogens capable of causing an array of
infectious diseases, especially in the rapidly expanding spectrum  of im m unologically and
m edically  com prom ised individuals [1]. Candida albicans, the m ost prevalent species of 
the Candida genus, is the m ost com m only isolated species, present in  approxim ately 70% 
of healthy adults [2]. C. albicans  norm ally  lives on the skin and inside the body, in places
such as the m outh, throat, gut and vagina, w ithou t causing any problem s; how ever, the 
fungus is also the leading cause of invasive fungal infection in  clinical settings [3]. A n 
invasive candidiasis carries the highest, up to 50% , attributable m ortality  rate am ong all
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nosocom ial pathogens [4 ]. Fungal biofilm -related infections have an enorm ous health  
im pact and econom ic consequences, including an estim ated 100,000 deaths and U SD  6.5 
billion in excess expenditure annually in the United States alone [5 ].
The occurrence of Candida bloodstream  infection (candidemia) and invasive candidia­
sis has been linked to the presence of artificial m edical devices, w hich provide an adherent 
surface that the pathogen colonizes and further proliferates on [6 ] . This process leads 
to the form ation of biofilm s, w hich  com prom ise consortia of fungal cells em bedded in 
extracellu lar m atrix  (EC M ) com ponents [7 ]. B iofilm  form ation plays a p ivotal role in 
healthcare-associated  infections and has been  tightly  linked to the developm ent of resis­
tance to available antifungal drugs [8 ] . An upsetting feature of biofilm -driven infections is 
related to the fact that fungal cells in biofilms have much higher resistance to antimicrobials 
as com pared w ith  their planktonic counterparts [9 ]. In  addition, fungal cells associated 
w ith  biofilm  com m unities disperse into the bloodstream  and dissem inate throughout the 
body, too com m only leading to the patient's death. Even though device rem oval is rec­
om m ended for patients w ith  C an d ida-in fected  m edical devices, rem oval of these gadgets 
presents a serious, often deadly risk to critically ill individuals [1 0 ].
The N ational Institutes of H ealth estim ate that biofilm s are responsible for over 80% 
of all m icrobial infections in the United States [11]. However, there are currently no drugs 
that w ould specifically target m icrobial biofilm s, including those form ed by  C. albican s . 
L ack  of potent antibiofilm  therapeutics m akes m ost attem pts to prevent, control or treat 
biofilm -based infections particularly  problem atic [12] . Thus, scientific research-fueled 
attem pts to decipher m echanism s that lead to biofilm  form ation and continuance could 
result in the development of novel antibiofilm treatm ent strategies and specific antifungals. 
In  fact, the scientific com m unity  has started to look for potential antibiotics to precisely 
target fungal biofilm  cells inducting physiological sw itches that w ould yield m ore drug- 
susceptible planktonic counterparts. A lthough screens of m ultiple chem ical libraries for 
antibiofilm activities were encouraging, it remains to be seen w hether they will advance to 
the developm ent of novel potent drugs [13]. A  handful of prom ising antibiofilm  agents 
have been  identified for their efficacy, including num erous fatty acids [14], extracellular 
complex carbohydrates [15], m ultiple enzymes [16], as well as various classes of secondary 
m etabolites, especially those of plant origin [17].
M any therapeutics currently  used in m odern m edicine are directly extracted from  
plants and som etim es also further chem ically  m odified. Cryptolepis sanguinolenta  (Lindl.) 
Schltr. (Periplocaceae)  is one of the num erous m edicinal A frican p lant species w hich  has 
been extensively studied in recent years [18]. This stemmed twining and scrambling shrub, 
w hich contains an orange-colored ju ice in the cut stem , has been used by som e traditional 
herbalists in the treatm ent of broad symptoms of fever, urinary and upper respiratory tract 
infections, m alaria, rheum atism  and venereal diseases [19]. The active com ponents found 
in this plant are know n to be the indoquinoline alkaloids, consisting m ainly of the indole 
and the quinoline m oieties. The m ajor alkaloid  of the roots, cryptolepine (5-m ethyl-5H - 
indolo[3,2-b]quinoline, Figure 1), w as reported to possess intricate biological effects, while 
neocryptolepine (5-m ethyl-5H -indolo[2,3-b ]quinoline, Figure 1 ) is a m inor alkaloid  of C. 
sanguinolenta [20]. DiMIQ (5,11-dimethyl-5H-indolo[2,3-b]quinoline, Figure 1) is a synthetic 
analog of neocryptolepine that has been used by our research team  as a base substrate for 
the chemical m odification and synthesis of new indoquinoline derivatives [21,22]. Some of 
these new ly synthetized am ino acid and peptide conjugates show ed strong preferential 
antifungal activities against C. albicans biofilm s [2 2 ].
The m ode of action of D iM IQ  and other indolo[2,3-b]quinolone derivatives is rather 
poorly understood. These chem icals are considered D N A  intercalating agents, w hich 
bind to circular double-stranded D N A  and induce D N A  cleavage in prokaryotic G ram ­
positive bacteria and eukaryotic fungi [23] as w ell as affecting m odel and natural m em ­
branes [24]. D iM IQ  w as also show n to stabilize the topoisom erase II-D N A  cleavable 
com plex in vitro [25]. This latter observation suggests that D iM IQ  could potentially inter­
act w ith other proteins and induce protein perturbations caused by  drug action in treated
biofilm  cells. H ere, w e h a v e  filled this research gap* by applying a label-free cellular pro­
teom ics to elucidate the speeific m echanism  u nderlying the antifungal action of D iM IQ  
against C. albicans biofilm s.
cryptolepine neocryptolepine
Figure 1. Structures of cryptolepine, neocryptolepine and DiMIQ.
2. Results
2.1. D iM IQ Is a Potent Inhibitor o fC . albicans Biofilms
D iM IQ  is an analogue of neocryptolepine w ith  an  additional m ethyl group in the 
11 position . C om parison of the calculated physicochem ical param eters of D iM IQ  and 
neocryptolepine revealed that the introduction of n m ethyl group caused no change in 
acid-base properties DDiMIQ pKg =  4. 64, neocryptolnpine pKa =  4.62). The obtained value 
for D iM IQ  is, how ever, sm yller than that determ ined experim entally  (7.45) [p6 ] . M ean­
w hile, such m odification changes the lipophilicity  properties expressed as log; D in  pH 
7.4. Log D is the decim al logarithm  of distribution coefficient and describes the overall 
ratio of the ionized and unionized m olecular forme b etw een the p o lar/n o n -p olar phases. 
Obtained log D vnlues (DiMIQ =  4.47, neocryptolepine =  4 .0t) show that DiM IQ displays a 
greater affinity for a lipophilic environm ent, w hich m ay im prove ids penetration ihrough 
biological m em branes. This characteristic makes DiM IQ a prom ising drug candidate from 
a pharm acolngical point of view.
O ur initial expnrim ents w ere designed to evaluate the antifungal activity  of D iM IQ  
against C. albicans biofilm s. We utilized a 96-w ell plate assay platform  for the assessm ent 
of the m etabolic activity  of frungal biofilm s using nn XTT (2,3-bie[2-m ethoxy-4-nitro-5- 
sulfophenyl]-2H -tetrazolium -5-parboxagilide inner salt) endpoint. D iM IQ  w as tested in 
the concentration range up to 500 n g /m L  and applied tw ice, at 6  and 24 h biofilm  growth 
tim e popnts (Figure gA ). D oses mf D iM IQ  of 3 1 3  n g /m L  and above compleWely inhibited 
the m etabolic activity of C. a lb k tn s  biofilm s. We further calculated the dneg concentration 
associated w fih  a 50°% reduction in  the m etabolic activfiy  e f  fiee treated fungnl biofilm s 
(ED56), w hich wns observed at 10.8 ±  0.2 n g/m L . All subsequent experiments on C. albicans 
biofilm s w ere carried e l the ED 5 0  concentration. W hen used during biofilm  seeding in 
a 6 -w ell plate assay, this selected dose of D iM IQ  lead a trem endouc effpct upon biofilm  
form etion yieldinn cnly  appronimately 44 ±  7%e c f  dry biomace as com pered to untreated 
controls (Figury 2B) .
Figure 2. Antibiofilm action of DiMCQ against C. albicans biofilms. (A) When used at concentrations 
greater than 31.3 n g /m L , DiMIQ com pletely inhibited fungal biofilm tormation in vitro. The drug 
was applied aftec 6 and 24 h of biofilm growth and iis entibiofilm impacp was determined using an 
XTT reduction assay. Data are expnessed as percent reduction compared to untreated controls. Mean 
valuen shown. (B) DiMIQ applied at the EDe  concentration of 10.8 n g /m L  dramatically reduced 
biofilm dry weight yield. Mean ±  SD values shown. * p <  0.01.
DiMI Q
2.2. D iM IQ Alters C. albicans Biofilm Cell Walls
The biochem ical com position of cell w alls is relatively  conserved am ong fungi and 
crucial for cel 1 w al 1 integrity, w hich further determ ines accom m odative stress response to 
both abiotic and biotic factors. We hypothesized that the exposure ol C. albicans biofilm s to 
DiM IQ m ay lead to alterations in overall cel 1 wall production and composition. Compared 
to untreated conlrols, the fraction off fungal cell w alls isolated from  D iM IQ -treated C. 
albicans biofilm s w as significantly increased by  nearly  57%  (Figure 3A ). The; com position 
of these cell w alls w as also altered in com parison to untreated controls. H exoses, such 
as glucose and m annose, build  the m ajor cell w all carbohydrate polym ers, glucans and 
m annans. Com pared to untreated fungal biofilm s, the level of hexoses in the cell w alls of 
D iM IQ -treated C. albicans  biofilm s w as elevated by  4.8%° to a total od 92.2%o. In addition, 
the exposure of fungal biofilms to DiM IQ had a minute detrimental effect on the confent of 
cell w all pentoses (arabinosef ribose, xylose), w hich  w as reduced from  9.2%o in untreated 
controls down lo 5.2%o (Figure 313).
Figure 3. DiMIQ-induced alterations in cell walls of C. albicans biofilms. (A) Exposure of biofilm 
fungal cells to DiMIQ resulted in increased cell wall production. Mean ±  SD values shown. * p < 0.01. 
(If) DiMIQ-treatment affected percentage carbohydrate profiles ol fungal cell walls by increasing the 
content of hexoses and simultaneously reducing pentoses. Mean values are shown.
2.3. D iM IQ A ffects the ECM  o f  <31. albicans Biofilm
A key feature of fungal biofilm s is th en  ability to produce the extracellu lat m atrix 
(ECM ), w hich em beds cells and constitutes an external protective barrier to the surround­
ing environm ent. Since the EC M  is oonsidered a crucial factor in biofilm  resritance to 
antifungals, w e hypothesized that D iM IQ  m ay have a strong effect on  both the content 
and the quality of the <31. albicans biofilm  ECM . C om pared to untreated conSrols, the ECM  
w s s  reduced by nearly 40% in fungal biofilms grow n  in the presence of DiM IQ (Figure 4A ). 
The EC M  com position in  control biofilm s consisSed of 86.3%° penfoses and 13°% hexoses. 
The content of arabinose, the m am  EC M  m onocarbohydrate, in  untreated controls w at 
79.7%°. The ECM  profile w as strongly affected in  the presence of DiM IQ, w hich noticeably; 
reduced the level of penfoses dow n to 11.9%° w ith  arabinose confent decreased to 5.8%°. 
Thele negative changel were atcom panied by an increate in  hexosel, w ith glucose content 
reachin g 73.3°% (Figure 4B ).
2.4. D iM IQ Induces Changes in the Cellular Proteom e o fC . albicans Biofilm Cells
A total of 725 proteins w ere identified from  C. albicans biofilm  cells (Figure 5A ). The 
proteome of untreated control biofilm  cells consisted of 693 proteins, w hereas 663 proteins 
w ere found in the proteom e of D iM IQ -treated  biofilm  cells. The tested indoquinoline 
derivatives either com pletely  inhibited the synthesis of 62 protein or decreased the pro­
duction of 257 proteins. D iM IQ also upregulated or induced the production of 186 and 32 
proteins, respectively. D iM IQ  had no effect on the production of 188 proteins (Figure 5 B). 
Calculated Z-score values are provided in Table S I.
Figuee 4. Negative impact of DiMIQ on the C. albicans biofilm extracellular matrix (ECM). (A) The 
presence of1 DfMIQ dramatically reduced the overall amount of ECM in Cungal bfofilms by nearly 
40%). Mean ±  SD values ehown. * c < 0-01. (P) DiMIQ treatmene massively modulated the percentage 
carbohydrate profile oc the ECM by a dramatic reduction in pentoses and a simultaneous increase in 
hexoses. Mean "values shown.
Figure 5. DiMIQ-induced changes in the cellular profile of C. albicans biofilms. (A) A set of 725 
proteins were identified in the tested fungal biofilms. The control proteome consisted of 693 proteins, 
whereao the DiMIQ-exposed proteome consisted of 663 proteins. The pool of common proteins 
contained 631 proteins. (B) Only 188 proieins were not affected by the DiMIQ treatment in the 
cellular proteome of Ci. albicans biofilms. There was a pool of 218 proteins that weee either drug- 
upregulated or induced, whereas 319 proteins were either downregulated or completely inhibited by 
the drug.
D iM IQ  and other indoquinoline alkaloids are considered D N A  intercalating agents 
capable of interaeiing w i°h D N A  topoisom erase II, an enoym e involved in  chrom osom e- 
aosociated D N A  replication [23] . O ur pooteomics analytis identified this opecific enzym e 
(TO P2, C A A LFM _C 406600W A ), w hich  w as 2.4-fold  upregulated in  the presence of the 
tested drug (Table S1) .
The identified proteine w ere functionally m apped babed on pathw ay assignm ents in 
the UniPcot and Kyolo Encyclopedia o i Genos and Genomeo (KEGG) databaees (Figure 6 ) 
[16,27- 29]. A  total of 394 different functions w ere represented by  91 enzym es classified 
in the pool of D iM IQ -u p regu lated /ind u ced  proteins. The m ajority  of pcoteins classified 
into this pool w ere involved in carbon m etabolism  (31 proteinsi, biosynthesis of am ino 
acids (22 o ro tfin s), biosynthesis of cofactors (15 proteins), oxidative phosphorylation (14 
proteins)e g ly co lysis/g lu coneogonesis (13), citrate cycie (TCA  cycle) (13 proteinb), pyru­
vate m etabolism  ( 1 2  proteins), g lyoxylate and dicarboxylate m etabolism  ( 1 1  proteins). 
Other, less abundant functional assignm ents involved the follow ing pathw ays: m ethane 
m etabolism  i9 ptoteins), peroxisom e (9 proteins), 2-oxycarboxylib a c it  metaboliom (9 pro­
teins}. D iM IQ  induced enzym es that w ere involved in  am ino acid m etabolism  such 
as cysteine and m ethionine m etabolism  ( 8  proteins), arginine and proline m etabolism  
(7 protem s), glycine, serine ane  threonine m etabolism  ( 6  proteins), arginine biosynthesis 
(5 proteins), phenylalanine, tyrosine and tryptophan btesynthesis (4 proteins). In addition, 
sm allet num bers of enzym es w ere m apped to pathw ays related to the m etaboliom  of car­
bohydrates (fructose and m annose m etabolism , starch and sucrose m etabolism , galactose 
m etabolism ) and nucleic acids (am inoacyl-tR N A  biosynthesis, RN A  transport, purine 
m etabolism , pyrimidine m etabolism , RNA degradation, amino sugar and nucleotide sugar 
m etabolism ).
Figure 6 . Functional mapping of the cellular proteome revealed targets for DiMIQ in C. albicans biofilms. (A- C) Proteins 
tvere grouped ba sed on aisignments of Kyoto Encyclopedia oF Genes and Genomes (KEGG) functional categories. Voronoi 
treemap layouts were used to visualize identified proteins, w hich were arranged into smaller clusters inside; higher 
level regions. This hierarchical classigication scheme was mapped to a to lor ramp starting with green (inhibited and 
downreculated proteins), passing yellow (no significanr drug effeti) and reaching red (upregulated and induced proteins). 
Quantitative differences in the proteome are based on calculated Z-score values (Table S1).
There wero 378 distinct; functions assigned to 74 enzym es in the pool of D iM IQ  
downregulaCed or inhibited proteins in C. albicans  biofilm s. The m ajority  oC proteins in 
this group w ere classified enbo the follow ing clusters: ribosom e (59 proteins), ovidative 
phosphoiylation ( I i  proteins), carbon m etabolism  (14 psoteins), p h igosom e ( 10 proteins), 
protein processing in  endoplasm ic reticulum  ( 1 0  proteins), pyruvate m etabolism  ( 8  pro­
teins), biosynthesis of cofactors (IB proteins). DiM IQ inhibited certain aspects of am inc acid 
m etabolism  such as the biosyntheses of a m ino acids ( 1 1  proCeins), alanine;, aspartate and 
glutamate m eiibolism  (10 proteins), valine, leucine and isoleucine degradation ( 6  Froteins) 
and beta-alanine m eiobolism  ( 6  proteins). D iM IQ  also negatively  im pacted pathw acs in­
volved in RNA transport (9 proteins), purine m etabolism  ( 6  proteins) or starch and sucrose 
m etabolism  (7 proteins).
3. Discussion
Biofilms constitute an ideal and unique lifestyle niche for microorganisms that provide 
suitable environm ental conditions for grow th and proliferation, even in the presence of 
toxic antifungals. In fact, m icrobial cells living in biofilm s are significantly m ore resistant 
to antim icrobial agents than their planktonic counterparts [30,31]. As biofilm s strongly 
contribute to the fungal pathogenicity, unraveling and understanding the m echanism s of 
drug resistance is a key approach to develop antibiofilm  treatm ent regim ens and success­
fully deal w ith the problem  of m edical device-associated fungal infecticns [32]. B eciu se o( 
the lack of effective antifungal therapy against biofilm  infections, the only recom m ended 
treatm ent for Candida bmfilm mfections is rem oval of the infected device [331 Ovec the last 
few] decades, only a handful of novel approachet that: theoretically  prevent and control 
biofilm  form ation and developm ent leave been  developed. These aniibiofilm  strategies 
involve non-adhesive coatings and le ll  repellents applied to m edical dev;ces, coatings
that actively release incorporated antim icrobials and biofilm  inhibitors and coatings w ith 
covalently tethered antim icrobials [34,35] . R ecent years have also brought the em ergence 
of resistance to the m ost com m on antifungal drugs; thus, there is an urgent need for the 
developm ent of alternative antifungal agents.
The indoquinoline alkaloids of C. sanguinolenta constitute a group of promising natural 
m etabolites w ith  an im pressive plethora of biological activities. Som e of these chem icals, 
such as D iM IQ , have been used as substrates for the chem ical m odification and synthesis 
of new  indoquinoline derivatives w ith  strong preferential antifungal activities against C. 
albicans biofilm s [22]. The m echanistic aspect of indoquinoline derivatives' action remains 
rather poorly  understood. Early  studies im plied that these chem icals m ay interact w ith  
DNA as well as target DNA topoisom erase II [23]. As DiM IQ and its derivatives appear as 
prom ising antibiofilm  agents against C. albicans biofilm s, defining the targeted pathw ays 
and deciphering the mechanism s of action of these compounds would be of great value for 
the design of innovative drug therapies in the future.
In this study, w e show ed D iM IQ  as an effective and potent inhibitor of C. albicans  
biofilm formation. At the ED 5 0  concentration of 10.8 n g /m L , the drug significantly reduced 
both m etabolic activ ity  and dry w eight biom ass (Figure 3 ) . The tested indoquinoline 
derivative had a strong effect on the quantity  of biofilm  cell w alls and resulted in nearly  
a 60%  increase in cell w all dry w eight biom ass as com pared to untreated controls. It is 
w orth  m entioning that D iM IQ  at the concentrations tested in  this study w as n ot toxic to 
m am m alian cells [36]. In addition, DiM IQ affected the cell wall com position profile, w hich 
led to elevated levels of glucans and m annans and sim ultaneous reductions in  cell w all 
pentoses. This finding suggests that the antibiofilm action of DiM IQ overwhelms C. albicans 
b iofilm s, w hich  in response produce excessive am ounts of cell w alls. These structures 
are crucial for fungal cells as they represent the m ultifactorial interface for interactions 
betw een the cell interior and the outer environm ent and play an im portant role in drug 
resistance [37] .
Like fungal cell walls, the ECM  produced by C. albicans biofilms provides a protective 
barrier to antifungal drugs by  drug sequestration and lim iting biofilm  penetration [7,31]. 
In this study, we showed that DiM IQ inhibited ECM  production by alm ost 40% (Figure 4 ). 
The drug had a strong effect on the chem ical com position of the biofilm  EC M , w hich, in 
the presence of DiM IQ, prim arily consisted of glucose and m annose and small amounts of 
arabinose. The latter is considered an extracellular carbon nutrient reservoir that is utilized 
by biofilm  fungal cells under nutritionally less favorable conditions, such as starvation or 
exposure to antifungals (Zarnow ski and Andes, unpublished). This finding also indicates 
that the antifungal activity of DiM IQ targets certain aspects of the m etabolism  in C. albicans 
biofilm  cells.
In this study, w e applied a label-free proteom ics analysis to explain the D iM IQ - 
induced protein abundance changes observed in C. albicans biofilm s and elucidate the 
dru g's m ode of action. W e discovered that D iM IQ  induced notable alterations in the 
cellular proteom ic profile (Figure 5 ). A  total of 725 unique proteins w ere identified in the 
tested fungal biofilm s. D iM IQ  had a negative effect on  319 identified proteins that w ere 
either partially downregulated or com pletely inhibited. Interestingly, D N A  topoisom erase 
II (T O I2 ) appeared to be not a d irect target for D iM IQ , bu t its action on this enzym e 
seem ed m ore indirect. A pparently, D iM IQ  interacted w ith  the D N A  structure, bu t m ore 
direct interactions were determined with nucleosom e core proteins (HHT21, HHF1, HTA2, 
H TZ1 and H TB1). It is therefore quite likely that the drug intercalated fragm ents of 
fungal D N A , w hich is a substrate for T O I2 . As the D N A  substrate w as inactivated in the 
presence of DiM IQ, TOP2 was produced by C. albicans cells at elevated levels, probably via 
a yet-to-be-identified feedback loop m echanism .
DiM IQ, the tested indoquinoline derivative, appeared as a potent inhibitor of protein 
synthesis (Figure 6 )  and its action had an enorm ous im pact on other m etabolic pathw ays 
(Figure 7 ). The drug had a strong inhibitory effect on num erous ribosomal proteins (RPL37B, 
RPL2, RPL82, RPS17B, C4YD X8, RPS14B, R PL 6 , RPS16A , RPL13, RPL10, C 4YF39, RPS21,
R PS21B, R PL16A , RPL4B, RPL14, RPL27A , R PL20B, RPS6A , RPL39, R PL17B, C 4YIL5, 
C 4YIP1, R PL21A , R PS9B, RPL11, C 4YK 99, RPL3, RPL28, RPS3, RPS27, RPS20, C4YM Q 1, 
R PL18, R PS19A , R PS0, RPS7A , R PL12, RI5L9B, R PL19A , R PL35, C 4YR43, R PS5L RPS25B, 
RPL10A, RPL2CA, RPS28B, P0P:,S->1:8, RPL5 andRP10). Interestingly cif> these targeted
proteins represented the protein SH 3-like dom ain superfam ily  (RPL2, RPL6, C 4YF39, 
R PL14, R PL27A  and RPL21A ), w hich  is involved in the translation process. W e also 
identified a pool of G TP-binding proteins that w ere dow nregulated by the tested agent 
(TEF1, RA C l, SE P7, RAS1, RSR1, C D C 10, ARF3, CDC11, ADE1L and GSP1).
Figure 7. Visualization og major DiMIQ-indeced alteeations in metabolic pathway networks in -he C. albicans biofilm 
cellular proteome. Interactions between proteins were predicted using the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING).
D iM IQ  inhibited several im portant cellular m ttabo lism  pathw ays related to cellu ­
lar energy production, such as oxidative phosphorylation (orf19.6035, V M A 8, V PH 1, 
orf19.364L Q C R 8, C YT1, ATP14, grf19.1480i V M A 5, V M A 4, V M A 13, PDH2, grf19.7590, 
PMA1, orfl9.1682 and NUC2) in d  pyruvate m etabolism  (orf1 9 .60 .6 , ERG1 0, P.YdSsi-EZ,, LEU42, 
M D H 1-3, FU M 11, G LX3 anil orf19.5611) (Figures 6 ond 7). <̂ P̂ ćaiig«es in tlae pyruvate 
m etabolism  pathw ay usually affect other m etabolic traits, such as alanine, aspartate and 
glutam ate m etabolism . In fact, our study revealed that D iM IQ  negatively  im pacted  sev­
eral proteins in this pathw ay (GA D1, GLT1, G D H 3, U G A 1, G LN 1, A D E13, A RG 1, CPA2, 
GFA1 and A D E1>). The drug im pacted the propanoate m etabolism  pathw ay (EH D3, 
A LD 6, U G A 1, ERG 10 and orf19.5611g w hich  directly intersects wieh tlae valine, leucine 
and isałeucine elrgradation pathway (EHD3, orf19.6066, ALD6, UGA1, ERG10 and P O U ). 
We also detected som e derogatory action of D iM IQ  on enzym es involved in beta-alanine 
m etabolism  (G A D 1, EH D 3, o rfa9.6066, A LD 6 and U G A 1). "The activ itg of this route in­
tersects w ith  thed ow nregu lated  alanine, asparlate and glutam aie m etabolie pathway. In 
hum ans, glutamine is the m ost abundant c ircu itin g  non-essential amino acid and is central 
.or w hole-body nitrogen balancs as well ts  for the nitoogen balance; of each organ; however, 
g lu iam ate p lay i ess ential role s in  most: b iological geowth and biofilm  form ation [38]. In 
.act, there are actively formed glutam ine gradients in m icrobial biofilm s- w hich delerm ine 
co-dependence betw een periphecal and central ce llc for glutam ine synthesis, w hich givns 
rise te  m etabolic com m ensalism  L39] . Based on our fin d in g . presented in this sbudy, w e 
conclude -h t- DiM IQ asti as aA effective inhibitor of ribosomos and subsequent translation, 
ab w ell as altesing processes relateb to cellular energy production along w ith correspond­
ing am ino acid mebabolic pafhw ays. We also diecovered that D iM IQ  inhibiteP glutamine; 
m etabolic pathways> w hich  m ay potentially lead fo the identification of v ital targets and 
prom ote tde developm ent of novel antibiofilm  grugs in the (uture [38,40].
Our experimental results showed that some DiM IQ-counteracting metabolic efforts oc­
curred in the proteome of C. albicans biofilms (Figures 6 ayd 7). dhe drug either upregulated
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or induced a total of 218 proteins. M ost of those proteins w ere involved in the follow ing 
pathw ays: citrate cycle (TCA  cycle) (ID H 1, LSC 1, PD A 1, SD H 12, PD B1, M D H 1-1, ID P1, 
ID H 2, CIT1, LSC 2, LPD 1, PCK1, M DH 1 and KG D 1), g lycolysis/gluconeogenesis (EN O1, 
AD H 2, ACS2, PDA1, PDB1, FBA1, CDC19, GPM 1, ACS1, HXK2, LPD1, FDH3, PCK1 and 
orf19.6178), oxidative phosphorylation (CO X5, orf19.4758, ATP7, SD H 12, C 4YI42, ATP2, 
ATP4, COX13, COX4, ATP16, ATP3, ATP5 and ALI1), pyruvate m etabolism  (MLS1, ACS2, 
PDA1, PDB1, M DH 1-1, CDC19, ACS1, LPD1, PCK1, M DH 1, ACC1 and ACH1), glyoxylate 
and dicarboxylate m etabolism  (M LS1, GCV2, ICL1, M D H 1-1, CIT1, FDH 1, LPD1, M DH 1, 
SH M 1), 2-oxocarboxylic acid m etabolism  (IDH 1, AAT1, IDP1, A RO 8 , IDH 2, CIT1, BAT22 
and ALT1). DiM IQ also upregulated peroxisomal enzym es (orf19.3684, SOD2, CAT2, IDP1, 
FAA4, FOX3, CTN3 and FAA2-3). Some of these pathways were also inhibited by the drug, 
w hich indicates the existence of m ultiple functionally redundant m etabolic routes and un­
derlies a robust m etabolism -adaptable biofilm  survival strategy [41]. O verall, stim ulation 
of these metabolic processes leads to increased energy production, w hich is probably quite 
lim ited in fungal biofilm  cells in the presence of D iM IQ . In addition, these pathw ays are 
functionally linked to other amino acid-based metabolic routes such as arginine and proline 
m etabolism  (PRO3, CAR2, AAT1, SPE3, PRO2, CAR1 and PUT2), cysteine and methionine 
m etabolism  (MDH1-1, AAT1, ARO 8 , SPE3, M ET 6 , MDH1 and BAT22), arginine biosynthe­
sis (AAT1, GD H 2, ALT1 and CA R1). D iM IQ  also upregulated the production of proteins 
involved in am inoacyl-tRN A  biosynthesis (TYS1, VAS1, FRS1, SES1, ILS1, orf19.6701 and 
GUS1). Am inoacyl-tRN As are recognized as potential antimicrobial drug targets and their 
inhibition has proven to be an effective antimicrobial strategy that im pedes an essential step 
of protein synthesis [42]. O ur results show ed that D iM IQ  did inhibit ribosom al proteins 
and stim ulated the biosynthesis of am inoacyl-tRN A m olecules. Thus, our finding m ay be 
explained by the presence of specific, yet unidentified m etabolic feedback loops resulting 
from the indirect inhibitory action of D iM IQ  on ribosom al proteins.
We also discovered that DiM IQ upregulated sets of proteins involved in carbohydrate 
m etabolism , such as fructose and m annose m etabolism  (FBA 1, PM I1, H XK 2, orf19.6178 
and M PG 1) or pentose phosphate pathw ay (TKL1, FBA 1, TAL1, orf19.6178 and RKI1). 
This phenom enon, along w ith  the stim ulation of fatty  acid m etabolism , could ju stify  the 
observed quantitative and qualitative alterations in C. albicans biofilm  fungal cell walls.
In conclusion, w e dem onstrate that D iM IQ  exhibits excellent antifungal activity 
against C . albicans  b iofilm s. The drug exerted a robust antibiofilm  action, w hich  altered 
biofilm formation and growth, cell w alls, the ECM and multiple metabolic pathways. These 
findings indicate that D iM IQ  and D iM IQ -based derivatives could provide an alternative 
approach to treating biofilm -associated Candida infections in the future.
4. Materials and Methods
4.1. M icrobes and Chemicals
D iM IQ  w as synthesized according to the m ethod described previously [43]. The 
negative logarithm  of the acid  dissociation constant (pK a) and the decim al logarithm  
distribution coefficient (log D) w ere calculated using the M arvinSketch softw are (version 
19.26.0, C hem A xon Ltd., Budapest, H ungary). A ll b iofilm  experim ents w ere done on C . 
albicans SN 250 strain (SC5314 background) [44], w hich w as stored in 15% glycerol frozen 
at - 8 0  °C. The fungus w as routinely  m aintained on yeast extract peptone (YPD ) agar 
plates (1% yeast extract, 2%  Bacto™  peptone, 2%  dextrose, 2%  Bacto™  agar), w hereas 
liquid cultures w ere grow n in broth  YPD  (1% yeast extract, 2%  Bacto™  peptone, 2%  
dextrose) rotating at 200 rpm  at 30 °C. A ll m edia com ponents w ere m anufactured by 
Becton, D ickinson and C om pany (Franklin Lakes, NJ, U SA ). For biofilm  assays, strains 
w ere cultured in filter sterilized R osw ell Park M em orial Institute (Buffalo, NY, USA ) 
m edium  1640 (RPM I), buffered w ith 4-m orpholinepropanesulfonic acid (MOPS) (Thermo 
Fisher Scientific, W altham, M A, USA) and pH adjusted to 7.0 [45]. All reagents used w ere 
acquired through the UW -M adison M aterial D istribution Services (M adison, W I, USA ).
4.2. Evaluation o f  M etabolic A ctivity in Fungal Biofilms
Ninety-six-well flat-bottom polystyrene plates were used to assess biofilm susceptibil­
ity to drug treatm ent. Fungal cell inocula (10 6  ce lls /m L ) w ere prepared out of overnight 
yeast cultures in YPD  at 30 °C , followed by dilution in RPM I-M O PS based on count num ­
bers w ith  an autom ated C ountess™  II cell counter (Invitrogen, Therm o Fisher Scientific, 
W altham , M A , USA ). O ne hundred pL of yeast cells per w ell w as seeded and inoculated 
plates w ere incubated at 37 °C. A fter a 6 -h biofilm  form ation period in  the w ells of 96- 
w ell m icrotiter plates, the biofilm s w ere w ashed tw ice w ith  phosphate-buffered saline 
(PBS, pH  7.2) in order to rem ove nonadherent cells, follow ed by  the addition of D iM IQ  
and fresh RPM I m edium . The drug w as used at concentrations up to 500 n g /m L . The 
procedure, including the drug treatm ent, w as repeated after 24 h and the plates w ere incu­
bated  for an additional period of 24 h, follow ed by  the X TT assay [46]. Briefly, solutions 
of XTT (2,3-bis[2-m ethoxy-4-nitro-5-sulfophenyl]-2H -tetrazolium -5-carboxanilide inner 
salt; 0.75 m g /m L ) and PM S (5-m ethylphenazinium  m ethyl sulfate; 3.20 m g /m L ) w ere 
prepared fresh for each set of assays and w ere kept aw ay from  light. Both reagants w ere 
purchased from  Therm o Fisher Scientific (W altham , M A, U SA ). To each w ell, 90 pL XTT 
and 10 pL phenazine m ethosulfate w ere added and incubated in the dark at 37 ° C for 1 h. 
A bsorbances at 492 nm  w ere m easured u sing an autom ated C ytation 5 im aging reader 
(BioTek, W inooski, VT, USA). The percent reduction in biofilm  growth w as calculated using 
the reduction in absorbance com pared to that of controls w ith no antifungal treatm ent.
4.3. C. albicans Biofilm Cell Wall and ECM  A nalyses
Six-w ell polystyrene plates w ere used to grow  fungal biofilm s for cell w all isolation 
and subsequent analysis. Fungal cell inocula w ere prepared as described above and 
biofilm s w ere seeded w ith  106  yeast cells per w ell. The nonadherent cells w ere rem oved 
after a 60-m in-long adherence incubation and 1 m L of fresh R PM I m edium  w as applied 
to each w ell. The biofilm s w ere grow n on an orbital shaker set at 50 rpm  at 37 °C  for 24 
h ; then, the m edium  w as replaced w ith  fresh RPM I or R PM I supplem ented w ith  D iM IQ  
follow ed by the incubation for another 24 h. Biofilm s w ere rem oved from  w ells w ith  a 
sterile spatula and harvested in sterile w ater ( 1  m L /w ell). The aliquots w ere com bined in 
a 15-m L Falcon tube and the biofilm  biom ass w as subjected to sonication in a w ater bath 
sonicator for 20 min. The sam ple w as next centrifuged at 2880x g  at 4 °C for 20 m in. This 
step separated the dissolved EC M  from  EC M -free fungal cells. F ive-m l of the collected 
filter-sterilized EC M  suspension w as placed in a clear 8 -m L glass screw  thread vial, dried 
overnight at 60 ° C  and subjected to m onocarbohydrate analysis [7,8 ]. Pelleted biofilm  
fungal cells were washed twice w ith PBS, resuspended in PBS and broken with glass beads 
five times for 1 min each [37]. Cell w alls were harvested by centrifugation, washed 5  times 
w ith  water, dried overnight at 60 °C  and dry w eights w ere determ ined. The isolated cell 
w alls w ere subjected to m onocarbohydrate analysis [7,8 ].
C arbohydrates in the biofilm  EC M  and cell w all fractions w ere analyzed based on 
the m odified procedures reported elsew here [7]. M onosugars w ere converted to alditol 
acetate derivatives [47] and then identified and quantified by gas chrom atography on a Shi- 
madzu GC-2010 system (Shimadzu, Colum bia, M D, USA). A Crossbond 50% cyanopropyl- 
m ethyl/50%  phenylm ethyl polysiloxane colum n w as used (15 m x 0.25 m m  w ith 0.25 pm 
film thickness, RTX-225, Restek, Bellefonte, PA, USA). The gas chrom atography conditions 
w ere as follow s: in jector at 220 °C , FID  detector at 240 °C , and a tem perature program  of 
215 °C for 2  min, then 4 °C /m in  up to 230 °C before holding for 11.25 min, run at constant 
linear velocity of 33.4 c m /s  and split ratio of 50:1.
4.4. C. albicans Biofilm Proteomics
Enzym atic " in  liqu id " digestion and m ass spectrom etric analysis w as done at the 
M ass Spectrometry Facility, Biotechnology Center, University of W isconsin— Madison. Two 
hundred pg of protein w as extracted by  precipitation w ith  15% T C A /6 0 %  acetone and 
then incubated at - 2 0  °C for 30 min. The m atrix or vesicle preparation was centrifuged at
16,000 x  g  for 1 0  m in, and the resulting pellets w ere w ashed tw ice w ith  ice-cold acetone, 
followed by an ice-cold M eO H  w ash. Pelleted proteins w ere resolubilized and denatured 
in 10 pL of 8  M  urea in 100 m M  N H 4 H C O 3  for 10 m in, then diluted to 60 pL for tryptic 
digestion with the following reagents: 3 pL of 25 mM DTT, 4.5 pL of acetonitrile, 36.2 pL of 
25 mM NH 4 H CO 3 , 0.3 pL of 1M Tris-HCl, and 6  pL of 100 n g /p L  Trypsin Gold solution in 
25 m M  NH 4 H CO 3  (Promega, M adison, W I, USA). Digestion w as conducted in two stages: 
first, overnight at 37  °C ; then, an additional 4 pL of trypsin solution w as added and the 
m ixture w as incubated at 42 °C  for an additional 2  h. The reaction w as term inated by 
acidification w ith 2.5% TFA to a final concentration of 0.3% and then centrifuged at 16,000 x 
g  for 10 m in. Trypsin-generated peptides w ere analyzed by  n an o L C -M S /M S  u sing the 
Agilent 1100 nanoflow system (Agilent, Santa Clara, CA, USA) connected to a hybrid linear 
ion trap-orbitrap  m ass spectrom eter (LTQ -O rbitrap, Therm o Fisher Scientific, W altham , 
M A, USA) equipped w ith a nanoelectrospray ion source. Capillary H PLC w as perform ed 
using an in-house fabricated colum n w ith an integrated electrospray emitter, as described 
elsew here [48]. Sam ple loading and desalting w ere achieved using a trapping colum n in 
line w ith the autosampler (Zorbax 300SB -C 18,5 pm, 5 x  0.3 mm, Agilent, Santa Clara, CA, 
U SA ). The LTQ -O rbitrap w as set to acquire M S /M S  spectra in a data-dependent m ode 
as follow s: M S survey scans from  300 to 2000 m / z  w ere collected in  profile m ode w ith  
a resolving pow er of 100,000. M S /M S  spectra w ere collected on the five m ost abundant 
signals in each survey scan. D ynam ic exclusion  w as em ployed to increase the dynam ic 
range and m axim ize peptide identifications. R aw  M S /M S  data w ere searched against a 
concatenated C. albicans amino acid sequence database using an in-house M ASCOT search 
engine [49]. Identified proteins w ere further annotated and filtered to 1.5% peptide and 
0.1% protein false discovery rate w ith Scaffold Q + version 4.10.0 (Proteom e Softw are Inc., 
Portland, OR, USA) using the protein prophet algorithm  [50].
4.5. Functional M apping o f  the C. albicans Biofilm Proteomes
The C. albicans control and DiM IQ-treated biofilm proteomes were analyzed using the 
U niProt K now ledgebase data, w hich contain reviewed U niProtK B/Sw iss-Prot entries [29, 
51] . The data w ere next analyzed using the K yoto Encyclopedia of Genes and G enom es 
(KEG G) [27,28]. In addition, the data w ere clustered using STR IN G  (the Search Tool for 
the R etrieval of Interacting G en es/P ro te in s) v.11.0 [52]. Each protein predicted from  the 
C. albicans genom e assigned a K EG G  O ntology ID  (KOID) w as obtained, and the specific 
pathw ay and superpathw ay m em bership inform ation retained. This w as then correlated 
w ith  the experim ental proteom e data, and the num ber of proteins expressed w ithin  a 
given pathw ay w as then determ ined. Tabulated proteins w ere presented as a percentage 
ou t of the total num ber of proteins predicted to belong to a given pathw ay from  the C. 
albicans genome, as determined by KEGG. The visualization of relative quantities of biofilm 
proteins w as also done using KEGG protein functional categorization. On the basis of this 
hierarchical classification schem e, Voronoi treem aps w ere constructed [53]. This approach 
divides screen space according to hierarchy levels in w hich the m ain functional categories 
determ ine screen sections on the first level, subsidiary categories on the second level, and 
so forth. The polygonic cells of the deepest level represented functionally classified proteins 
and were colored according to the relative abundance of each protein that w as determined 
based on total counts of corresponding trypsin-digested peptides. Voronoi treem aps were 
prepared w ith Paver (version 2.1.9, D ECO D O N  Softw are UG, Greifsw ald, Germ any).
4.6. Statistical Analysis
D atasets w ere analyzed using one-w ay analysis of variance (ANOVA) and the post- 
hoc Tukey Honestly Significance Difference test and w ith Bonferroni and Holm interference 
com parisons. Statistically  significant outliers w ere identified based on  the G rubbs' test. 
D ata w ere processed w ith GraphPad Prism  9 for W indow s 64-bit (version 9.0.0).
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